Background and purpose
There are only a limited number of reports of treatment of prostate cancer with permanent prostate seed I125 brachytherapy (PPB) in Europe. We describe results from one Finnish institution having treated 444 patients with a follow-up of eight years.
Material and methods
Morbidity was evaluated by International Prostate Symptom Score and International Index of Erectile Function questionnaires. Urine flow, residual urine volume and the PSA values were measured pre-treatment and during follow-up. Any additional treatments were recorded.
PPB was well tolerated. Median IPSS increased from 8 at baseline to 18 at three months post-therapy and returned to baseline score within 12 months. Median urine flow decreased from 15.2 ml/s at baseline to 10.2 ml/s at three months and returned to baseline value within two years. Acute urinary retention, potency preservation and severe proctitis were observed in 11%, 86% and 2% of patients, respectively. The PSA bounce was observed in 13% and PSA nadir ⩽0.5 μg/l was reached by 81% of patients. Disease-free survival (DFS) was 90.2%. In the Cox regression analysis, the independent predictors of DFS were risk group and PSA nadir ⩽0.5 μg/l (p < 0.0001 for both). PC-specific survival was 98.5% and overall survival was 94.6%.
Our results are in concordance and comparable with other reports on PPB.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Radiotherapy and Oncology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Brachytherapy for prostate cancer: a systematic review of clinical and cost effectiveness.Eur Urol. 2003; 44: 40-46
- Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide.Brachytherapy. 2007; 6: 16-25
- Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.Int J Radiat Oncol Biol Phys. 2003; 57: 645-653
- 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy.Int J Radiat Oncol Biol Phys. 2001; 51: 31-40
- 12-Year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer.J. Urol. 2005; 173: 1562-1566
- Multi-institutional analysis of long-term outcome for stages T1–T2 prostate cancer treated with permanent seed implantation.Int J Radiat Oncol Biol Phys. 2007; 67: 327-333
- Results of permanent prostate brachytherapy, 13 years of experience at a single institution.Radiother Oncol. 2004; 71: 23-28
- Selecting patients for exclusive permanent implant prostate brachytherapy: the experience of the Paris Institute Curie/Cochin Hospital/Necker Hospital group on 809 patients.Int J Radiat Oncol Biol Phys. 2008; 71: 1042-1048
- Early biochemical outcomes following permanent interstitial brachytherapy as monotherapy in 1050 patients with clinical T1–T2 prostate cancer.Radiother Oncol. 2006; 80: 57-61
- Long-term outcomes and morbidity after I125 brachytherapy for localised prostate cancer: an early UK series.Clin Oncol (R Coll Radiol). 2005; 17: 127
- ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer.Radiother Oncol. 2000; 57: 315-321
- A prospective analysis of long-term quality of life after permanent I-125 brachytherapy for localised prostate cancer.Radiother Oncol. 2007; 84: 135-139
- Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy.Urology. 2007; 70: 548-553
- Relationship of the International Prostate Symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy.Brachytherapy. 2006; 5: 9-13
- Urinary morbidity following ultrasound-guided transperineal prostate seed implantation.Int J Radiat Oncol Biol Phys. 1999; 45: 59-67
- Complications following permanent prostate brachytherapy.Eur Urol. 2002; 41: 427-433
- Post-brachytherapy transurethral resection of the prostate in patients with localized prostate cancer.J Urol. 2004; 172: 108-111
- Toxicity and early biochemical outcomes from 125iodine prostate brachytherapy in the UK. A prospective study.Clin Oncol (R Coll Radiol). 2004; 16: 95-104
- Erectile function after prostate brachytherapy.Int J Radiat Oncol Biol Phys. 2005; 62: 437-447
- Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years.Urology. 2007; 69: 338-342
- The seven-year preliminary results of brachytherapy with Iodine-125 seeds for localized prostate cancer treated at a Brazilian single-center.Int Braz J Urol. 2007; 33 ([discussion 762–3]): 752-762
- PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time.Int J Radiat Oncol Biol Phys. 2006; 64: 512-517
- PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure.Cancer Radiother. 2007; 11: 105-110
- Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy.Int J Radiat Oncol Biol Phys. 2005; 61: 1299-1305
Published online: January 23, 2009
Accepted: December 9, 2008
Received in revised form: November 24, 2008
Received: February 5, 2008
© 2009 Elsevier Ireland Ltd. Published by Elsevier Inc. All rights reserved.